Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements (Tables)

v3.20.1
Research and Development Agreements (Tables)
3 Months Ended
Mar. 31, 2020
Schedule of Research and Development Revenues Disaggregated by Location

Research and development revenue is attributable to regions based on the location of our collaboration partner's parent company headquarters.  Research and development revenues disaggregated by location were as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2020

 

 

2019

 

Japan

 

$

333

 

 

$

6,413

 

United States

 

 

1,467

 

 

 

 

Total research and development revenue

 

$

1,800

 

 

$

6,413

 

 

Millennium Pharmaceuticals Inc  
Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements

Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”) and were as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2020

 

 

2019

 

Takeda Individual Project Agreement

 

 

 

 

 

54

 

Takeda Development and License Agreement

 

 

147

 

 

 

6,114

 

Takeda Multi-Target Agreement

 

 

186

 

 

 

245

 

Total research and development revenue

 

$

333

 

 

$

6,413

 

Takeda Pharmaceuticals Inc  
Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from Research and Development Agreements Deferred revenue, other liabilities for co-share payments and accounts receivable balances from the research and development agreements with Takeda, who is a related party, were as follows (in thousands):

 

 

 

March 31, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Accounts receivable

 

$

1,300

 

 

$

408

 

Liabilities

 

 

 

 

 

 

 

 

Other current liabilities

 

$

7,754

 

 

 

 

Deferred revenue, current

 

 

8,773

 

 

 

8,780

 

Deferred revenue, non-current

 

 

1,355

 

 

 

441

 

Other liabilities

 

 

1,746

 

 

 

 

Total liabilities

 

$

19,628

 

 

$

9,221